Literature DB >> 27069158

Impact of Neoadjuvant Chemotherapy Among Patients with Pancreatic Fistula After Gastrectomy for Advanced Gastric Cancer.

Takashi Kosaka1, Hirotoshi Akiyama2, Hirochika Makino2, Jun Kimura2, Ryo Takagawa2, Hidetaka A Ono2, Chikara Kunisaki3, Itaru Endo2.   

Abstract

BACKGROUND: Neoadjuvant chemotherapy (NAC) has been widely adopted for patients with advanced gastric cancer; however, the safety of gastrectomy with D2 lymphadenectomy followed by NAC has not yet been evaluated. We retrospectively analyzed the influence of NAC on morbidity and mortality after gastrectomy in patients with advanced gastric cancer. PATIENTS AND METHODS: A series of 364 patients with advanced gastric cancer who underwent gastrectomy without pancreatectomy between January 2008 and December 2010 at eight hospitals registered to the Yokohama Clinical Oncology Group were studied retrospectively. There were 330 patients who underwent surgical treatment immediately after diagnosis (surgery alone group) and 34 patients (NAC group) who first received NAC and then underwent surgical resection.
RESULTS: Although there were no significant differences in the morbidity rate between the two groups, postoperative pancreatic fistula was more often observed in NAC patients than in patients of the group treated with surgery alone [5 cases (14.7%) vs. 11 cases (3.3%); p=0.011]. In the univariate analysis, NAC (p=0.029), bursectomy (p<0.001) and operative bleeding (≥300 ml, p=0.002), were significantly correlated with postoperative pancreatic fistula, and NAC [odds ratio (OR)=4.901, 95% confidence interval (CI)=1.455-16.67; p=0.010] and bursectomy (OR=11.2, 95% CI=3.460-37.04; p<0.001) were independent risk factors for postoperative pancreatic fistula by multivariate analysis. The incidence of postoperative pancreatic fistula was 40.0% among patients who underwent gastrectomy with bursectomy followed by NAC.
CONCLUSION: The incidence of pancreatic fistula in patients treated with NAC and bursectomy was significantly higher than that in other patients. Bursectomy may be discouraged for the prevention of pancreatic fistula from gastrectomy following NAC. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Neoadjuvant chemotherapy; pancreatic fistula; surgical complication

Mesh:

Year:  2016        PMID: 27069158

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.

Authors:  Kinro Sasaki; Shinichi Onodera; Kichiro Otsuka; Hitoshi Satomura; Eigo Kurayama; Tsukasa Kubo; Masakazu Takahashi; Jun Ito; Masanobu Nakajima; Satoru Yamaguchi; Kazuhito Miyachi; Hiroyuki Kato
Journal:  Med Oncol       Date:  2017-07-13       Impact factor: 3.064

2.  The role of bursectomy in the surgical management of gastric cancer: a meta-analysis and systematic review.

Authors:  Konstantinos Perivoliotis; Ioannis Baloyiannis; Dimitrios Symeonidis; Konstantinos Tepetes
Journal:  Updates Surg       Date:  2020-06-03

3.  Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database.

Authors:  Shinichi Umeda; Mitsuro Kanda; Koki Nakanishi; Seiji Ito; Yoshinari Mochizuki; Hitoshi Teramoto; Kiyoshi Ishigure; Toshifumi Murai; Takahiro Asada; Akiharu Ishiyama; Hidenobu Matsushita; Dai Shimizu; Daisuke Kobayashi; Chie Tanaka; Michitaka Fujiwara; Kenta Murotani; Yasuhiro Kodera
Journal:  Surg Today       Date:  2020-11-10       Impact factor: 2.549

4.  Pancreatic Fistula after D1+/D2 Radical Gastrectomy according to the Updated International Study Group of Pancreatic Surgery Criteria: Risk Factors and Clinical Consequences. Experience of Surgeons with High Caseloads in a Single Surgical Center in Eastern Europe.

Authors:  Alexandru Martiniuc; Traian Dumitrascu; Mihnea Ionescu; Stefan Tudor; Monica Lacatus; Vlad Herlea; Catalin Vasilescu
Journal:  J Gastric Cancer       Date:  2021-03-18       Impact factor: 3.720

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.